Minority Health Archive


Cyrus-David, Mfon S. (2006) THE FUTURE OF WOMEN OF MINORITY RACE/ETHNICITY IN BREAST CANCER CHEMOPREVENTION THERAPY. Ethnicity & Disease, 16 (1). pp. 216-222. ISSN 1049-510X

Full text not available from this repository.


Women of minority race/ethnicity have been underrepresented in United States-based breast cancer chemoprevention trials. Searches of Medline between 1966 and 2004 were done with priority given to recent reports (1996–2004), and references from bibliographies of relevant articles. Large chemoprevention trials have reported significant breast cancer risk reduction and increased risk of serious adverse events in tamoxifen-treated, high-risk women, which illustrates the need to carefully assess the risk/benefits of this therapy. The mathematical model used for this purpose in the United States-based trials has resulted in the inclusion of very few women of minority racial/ethnic backgrounds. The continued use of this risk assessment that has not been adequately validated for its usefulness in non-Caucasian populations, should be reviewed, especially given that adequate alternative nonmathematical models exist. Current and future chemoprevention trials should also use nonmathematical selection criteria to ensure that eligible underrepresented minorities are adequately included in these trials.

Export/Citation:EndNote | BibTeX | Dublin Core | ASCII (Chicago style) | HTML Citation | OpenURL | Reference Manager
Social Networking:

Item Type: Article
Additional Information: After clicking on link, scroll down the page to find the article.
Uncontrolled Keywords: Breast Cancer Chemoprevention, Selective Estrogen Receptor Modulators
Subjects: Health
Health > Public Health > Chronic Illness & Diseases > Cancer
Related URLs:
Depositing User: Users 141 not found.
Date Deposited: 22 Dec 2008
Last Modified: 27 May 2011 13:22
Link to this item (URI): http://health-equity.lib.umd.edu/id/eprint/1258

Actions (login required)

View Item